Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAT2A | P31153 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5718492 | 0.85 | ALDH1A1 (0.50) | MEN1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL5718587 | 0.84 | MEN1 (0.68) | MEN1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL5351065 | 0.81 | ATM (0.52) | MEN1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL7843289 | 0.80 | TSHR (0.45) | MEN1KMT2ALMNAL3MBTL1ALDH1A1 | |
| SCHEMBL11696380 | 0.79 | LMNA (0.50) | MEN1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL28738835 | 0.78 | MEN1 (1.00) | MEN1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL23119669 | 0.78 | LMNA (0.67) | MEN1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL11348908 | 0.78 | LMNA (0.62) | MEN1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL11314421 | 0.77 | MAPT (0.48) | MEN1KMT2ALMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL11692618 | 0.77 | MEN1 (0.50) | MEN1KMT2ALMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4670486-A | Polymer composition pigmented with copper or nickel complexes of ligands containing a semicarbazone moiety | CIBA-GEIGY CORPORATION (US) | 1987-06-02 | — | — | US | claimed |
| US-7262284-B2 | Method for producing disazo pigments | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| US-20060167236-A1 | Method for producing disazo pigments | CLARIANT GMBH (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1132432-B1 | Preparation process of pigments | CLARIANT FINANCE BVI LTD (VG) | 2006-02-08 | — | — | EP | disclosed |
| EP-1517962-A1 | METHOD FOR PRODUCING DISAZO PIGMENTS | Clariant GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000947-A1 | METHOD FOR PRODUCING DISAZO PIGMENTS | CLARIANT GMBH (DE) | 2003-12-31 | — | — | WO | disclosed |
| US-6512115-B2 | Preparing symmetrically disubstituted triphendioxazine compounds by cyclizing amino substituted benzoquinone intermediates in the presence of manganese oxide and sulfuric acid | CLARIANT FINANCE (BVI) LIMITED (VI) | 2003-01-28 | — | — | US | disclosed |
| US-20010031864-A1 | Preparation of pigments | CLARIANT FINANCE (BVI) LIMITED | 2001-10-18 | — | — | US | disclosed |
| EP-1132432-A2 | Preparation process of pigments | Clariant Finance (BVI) Limited (VG) | 2001-09-12 | — | — | EP | disclosed |
| EP-0168343-B1 | METAL COMPLEXES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN DYEING HIGH-MOLECULAR ORGANIC MATERIALS | CIBA-GEIGY AG (CH) | 1991-05-02 | — | — | EP | disclosed |
| US-4263205-A | FOR COLORING POLYMERS, LACQUERS | CIBA-GEIGY CORPORATION (US) | 1981-04-21 | — | — | US | disclosed |
| US-4229344-A | Monazo pigments containing hydroxynaphthoylaminobenzimidazalone radical | CIBA-GEIGY CORPORATION (US) | 1980-10-21 | — | — | US | disclosed |
| US-4220586-A | FASTNESS TO LIGHT, OVER-LACQUERING, MIGRATION, WEATHERING, AND HEAT | CIBA-GEIGY CORPORATION (US) | 1980-09-02 | — | — | US | disclosed |
| US-4116959-A | ISOINDOLINE PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4088641-A | YELLOW TO RED SHADES | CIBA-GEIGY CORPORATION (US) | 1978-05-09 | — | — | US | disclosed |
| US-4052410-A | YELLOW, PLASTICS, LACQUERS | CIBA-GEIGY CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
| US-4012371-A | Benzinaldazolyl-, quinolonyl-, or phenmorpholonylazo-3-cyano-4-methyl-1,2-[1',2']-benz-[4',5']-imidazolo-6-hydroxypyridine colorants | CIBA-GEIGY CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |
| US-3979386-A | YELLOW, COLORFASTNESS | CIBA-GEIGY CORPORATION (US) | 1976-09-07 | — | — | US | disclosed |
| US-3963694-A | AZO PIGMENTS, POLYESTERS, CELLULOSE ETHERS AND ESTERS | CIBA-GEIGY CORPORATION (US) | 1976-06-15 | — | — | US | disclosed |
| US-3956266-A | DISAZO DYES | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167236-A1 | Method for producing disazo pigments | TYR, IPO4, CBR3 | MEN1 2054/4885KMT2A 2138/4885LMNA 1543/4885 |
| US-20010031864-A1 | Preparation of pigments | SCO2, PPOX, PRDX4 | MEN1 216/4885KMT2A 1664/4885LMNA 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.